Our Presence

USA | India

Email Us

info@atvigilx.com

Best Pharma Outsourcing Company in India for US Biotech

👤 Dr. Sornaraja Thasma | 🗓️ 12 Nov, 2026 | 📂 Pharmacovigilance

best pharma outsourcing company in India for US biotech

Looking for a pharma outsourcing company in India? Atvigilx supports US biotech with pharmacovigilance, drug safety and regulatory services.

Atvigilx: The Best Pharma Outsourcing Company in India for US Biotech Companies

The US biotechnology industry is growing rapidly, with emerging biotech companies developing innovative therapies and expanding their clinical and commercial operations. However, managing pharmacovigilance, adverse event reporting, regulatory documentation, and ongoing drug safety activities can put considerable pressure on internal teams, particularly for small and mid-sized biotech companies.

This is why many US biotech companies consider outsourcing selected pharmaceutical operations to experienced service providers in India. Access to qualified life sciences professionals, flexible operational support, and experience with international regulatory requirements can help companies manage their responsibilities without building every function internally.

When evaluating the best pharma outsourcing company in India, biotech companies need more than competitive pricing. They need a partner who understands US regulatory expectations, maintains consistent quality standards, and can support drug safety activities throughout the product lifecycle.

Atvigilx supports pharmaceutical and biotechnology companies through specialized pharmacovigilance, drug safety, regulatory affairs, and GCP services, helping US biotech organizations manage operational requirements while maintaining a strong focus on patient safety and regulatory compliance.

Why Do US Biotech Companies Outsource Pharmaceutical Services to India?

Biotechnology companies often work with limited teams while managing demanding development timelines and regulatory responsibilities. Outsourcing selected activities can help them access additional capabilities without building every function internally.

Some of the main reasons companies consider outsourcing to India include:

Access to specialized expertise

Pharmacovigilance and regulatory activities require people with knowledge of safety reporting, medical review, regulatory documentation and applicable guidelines. An outsourcing partner can provide access to teams with relevant life sciences experience.

Operational flexibility

A biotech company may need support for a specific activity, such as ICSR processing or literature screening, or require ongoing assistance across several safety operations. Outsourcing can provide flexibility as workloads and product requirements change.

Cost management

Maintaining dedicated internal teams for every operational function can increase costs. Outsourcing selected activities may help companies manage resources while retaining the internal oversight needed for quality and compliance.

Support for international regulatory requirements

Companies operating in multiple markets must understand the reporting and documentation requirements applicable to each region. An experienced service provider can support regulatory activities across different markets.

More time for core development activities

By assigning selected operational tasks to an external partner, biotech teams can give more attention to research, clinical development, product strategy and business priorities.

Outsourcing does not remove a company’s regulatory responsibilities. The biotech company remains responsible for appropriate oversight of outsourced activities, including vendor qualification, written agreements, performance monitoring and quality controls.

Why Do US Biotech Companies Outsource Pharmaceutical Services to India?

Biotechnology companies often work with limited teams while managing demanding development timelines and regulatory responsibilities. Outsourcing selected activities can help them access additional capabilities without building every function internally.

Some of the main reasons companies consider outsourcing to India include:

Access to specialized expertise

Pharmacovigilance and regulatory activities require people with knowledge of safety reporting, medical review, regulatory documentation and applicable guidelines. An outsourcing partner can provide access to teams with relevant life sciences experience.

Operational flexibility

A biotech company may need support for a specific activity, such as ICSR processing or literature screening, or require ongoing assistance across several safety operations. Outsourcing can provide flexibility as workloads and product requirements change.

Cost management

Maintaining dedicated internal teams for every operational function can increase costs. Outsourcing selected activities may help companies manage resources while retaining the internal oversight needed for quality and compliance.

Support for international regulatory requirements

Companies operating in multiple markets must understand the reporting and documentation requirements applicable to each region. An experienced service provider can support regulatory activities across different markets.

More time for core development activities

By assigning selected operational tasks to an external partner, biotech teams can give more attention to research, clinical development, product strategy and business priorities.

Outsourcing does not remove a company’s regulatory responsibilities. The biotech company remains responsible for appropriate oversight of outsourced activities, including vendor qualification, written agreements, performance monitoring and quality controls.

What Should US Biotech Companies Evaluate Before Choosing an Outsourcing Partner?

Selecting a pharmaceutical outsourcing provider is both a business and a compliance decision. The right partner should understand the company’s operational requirements and have the capabilities to support its pharmacovigilance and regulatory activities.

Before entering an outsourcing agreement, US biotech companies should evaluate several important factors.

1. Experience in Pharmacovigilance and Drug Safety

Assess whether the provider has experience with ICSR processing, adverse event management, literature monitoring, signal detection, and aggregate safety reporting. Experience across clinical development and post-marketing activities can also be valuable.

2. Knowledge of International Regulatory Requirements

The provider should understand relevant regulatory expectations across markets, including FDA, EMA, MHRA, and Health Canada requirements. This is particularly important for companies conducting clinical studies or commercializing products internationally.

3. Quality Management and Compliance Processes

Review the provider’s standard operating procedures, quality management practices, documentation controls, training processes, and deviation management procedures. Ask how quality oversight and service performance will be maintained.

4. Data Security and Confidentiality

Pharmacovigilance operations involve sensitive patient and safety information. Evaluate data protection arrangements, access controls, confidentiality procedures, and the provider’s approach to applicable privacy requirements.

5. Communication and Operational Flexibility

Clear communication, defined escalation procedures, reporting responsibilities, and the ability to accommodate changing workloads are important for maintaining effective outsourcing relationships.

A capable outsourcing partner should be able to explain how its processes fit into the client’s existing pharmacovigilance system rather than offering services without understanding the company’s operating model.

Why Choose Atvigilx for Pharmacovigilance and Regulatory Support?

Atvigilx provides pharmacovigilance, regulatory affairs and GCP services for pharmaceutical, biotechnology, CRO and medical device companies. Its operations in the USA and India support companies seeking specialized life sciences services across different markets.

The company’s website highlights more than 20 years of industry experience and over 1,000 safety cases processed. These capabilities provide a starting point for companies assessing its experience and service scope.

For US biotech companies, Atvigilx’s capabilities are particularly relevant in areas where ongoing safety activities, regulatory documentation and quality oversight require dedicated support.

Pharmacovigilance and drug safety experience

Atvigilx supports drug safety activities ranging from adverse event intake and ICSR management to literature screening, medical review, signal detection and aggregate reporting. These services can support companies managing safety information during clinical development and after product approval.

Regulatory affairs and medical writing support

Regulatory documentation and submission activities require accuracy and an understanding of applicable requirements. Atvigilx provides regulatory affairs and medical writing support, including regulatory strategy, eCTD publishing, product labelling and safety-related reports.

Support across regulatory markets

The company’s published portfolio identifies experience across regulatory markets and authorities, including the FDA, EMA, MHRA, Health Canada and CDSCO. This is relevant for companies managing products or regulatory activities across more than one market.

Flexible service support

Companies may require assistance with a particular activity or ongoing operational support. Atvigilx’s service range allows biotech companies to discuss requirements based on their product, workload and internal resources.

Atvigilx's Pharmacovigilance, Regulatory Affairs and GCP Services

Atvigilx’s services cover three main areas: Drug Safety and Pharmacovigilance, Regulatory Affairs and Good Clinical Practice. Together, these capabilities support companies managing clinical safety, regulatory documentation and ongoing product safety responsibilities.

1. Drug Safety and Pharmacovigilance Services

Pharmacovigilance is an important part of product development and post-marketing safety management. Companies need processes for collecting, reviewing, assessing and reporting adverse event information.

Atvigilx provides support across several drug safety activities, including:

  • Individual Case Safety Reports (ICSRs): Case intake, processing, medical review and submissions.
  • Adverse Event Management: Adverse event intake and safety information management.
  • Literature Screening and Review: Identification and review of relevant safety information from published literature.
  • SAE and SUSAR Management: Clinical safety management and reporting support.
  • Aggregate Safety Reporting: Preparation of PSURs, PBRERs and DSURs.
  • Signal and Risk Management: Signal detection, benefit-risk assessment and risk management plans.
  • PV Quality and Compliance: PV audits, SOP development and compliance support.
  • PV System Support: PSMF setup and maintenance, QPPV services and EudraVigilance setup and maintenance.
  • Medical Device Vigilance: Safety reporting, risk assessment and post-market surveillance support.
  • Local Pharmacovigilance: Support for country-specific pharmacovigilance activities.

These services can help companies manage individual safety activities or discuss ongoing support for their pharmacovigilance operations.

2. Regulatory Affairs Services

Regulatory requirements can vary depending on the product, target market and stage of development. Companies need appropriate documentation and regulatory planning to support product submissions and lifecycle activities.

Atvigilx’s regulatory affairs services include:

  • Regulatory strategy consulting.

  • New product marketing authorizations.

  • Regulatory gap analysis and remediation.

  • Regulatory due diligence.

  • API and Drug Master File (DMF) support.

  • Chemistry, Manufacturing and Controls (CMC) regulatory advisory.

  • ANDA and Marketing Authorization Holder (MAH) support.

  • eCTD publishing and submission.

  • Pharmaceutical product labelling.

These services can support companies preparing regulatory documentation, reviewing submission requirements and managing selected regulatory activities.

3. Good Clinical Practice (GCP) Services

GCP requirements are important for protecting trial participants and maintaining the quality and integrity of clinical trial data. Atvigilx also lists GCP-related services for companies involved in clinical research.

Its GCP services include:

  • GCP audits.

  • Clinical trial monitoring.

  • Bioanalytical monitoring.

  • Bioequivalence study monitoring.

These capabilities provide additional support for organizations managing clinical research activities and related quality requirements.

Atvigilx's Expertise Across Pharmaceutical and Healthcare Portfolios

Pharmacovigilance and regulatory requirements can differ based on the type of product being developed or marketed. A pharmaceutical product, medical device, biological product or dietary supplement may involve different safety considerations and reporting needs.

Atvigilx’s published product and industry portfolio includes the following categories.

Product or Industry CategoryRelevant Support Areas
PharmaceuticalsDrug safety monitoring, adverse event reporting and pharmacovigilance
Medical DevicesDevice vigilance, adverse event reporting and post-market surveillance
Biological and Biosimilar ProductsSafety monitoring, signal detection and risk management
HerbalsSafety monitoring and pharmacovigilance support
Dietary SupplementsAdverse event assessment and safety monitoring

The company’s website also identifies regulatory experience across the following authorities and markets:

  • US Food and Drug Administration (FDA)

  • European Medicines Agency (EMA)

  • Medicines and Healthcare products Regulatory Agency (MHRA)

  • Health Canada

  • Central Drugs Standard Control Organisation (CDSCO)

For biotech companies with products intended for more than one market, this range of product and regulatory experience can be relevant when assessing a potential outsourcing partner.

How Atvigilx's Capabilities Align With US Biotech Outsourcing Needs

Evaluation CriteriaUS Biotech RequirementsAtvigilx Capabilities
Drug safety operationsAccurate case processing and safety monitoringICSR processing, adverse event intake, SAE/SUSAR management
Regulatory reportingPeriodic safety documentationPSUR, PBRER, DSUR and RMP support
Safety surveillanceIdentification and assessment of potential risksLiterature monitoring and signal detection
Regulatory expertiseSupport across international marketsFDA, EMA, MHRA, Health Canada and CDSCO-related support
Operational flexibilitySupport according to project requirementsFlexible pharmacovigilance outsourcing
Clinical safetySafety oversight during clinical developmentClinical safety management and GCP support

The right outsourcing arrangement should be based on service expertise, quality processes, communication, data security, and the company’s regulatory responsibilities rather than price alone.

How Atvigilx Supports US Biotech Companies Through the Product Lifecycle

Pharmacovigilance and regulatory activities are not limited to the period after a product reaches the market. Safety and documentation requirements can arise during clinical development and continue throughout the product lifecycle.

Atvigilx is a dedicated pharmacovigilance and regulatory services brand of ProRelix Research. ProRelix Research is an established Contract Research Organisation (CRO) with broader clinical development capabilities, including clinical operations, clinical data management and medical writing.

This relationship provides a wider life sciences context for understanding how clinical development and product safety activities connect.

The following stages illustrate where relevant support may be required.

1. Clinical Development

During clinical trials, companies need processes for managing adverse events and serious adverse events. Depending on the study and assigned responsibilities, support may include clinical safety management, SAE and SUSAR reporting, safety documentation and monitoring-related activities.

2. Regulatory Preparation

As a product moves through development, regulatory documentation becomes increasingly important. Companies may require support with DSUR preparation, safety narratives, protocol review, risk management documentation and regulatory planning.

3. Product Approval and Market Entry

Before entering a market, companies may need assistance with regulatory submissions, eCTD publishing, product labelling and marketing authorization activities. The requirements depend on the product and the target regulatory authority.

4. Post-Marketing Safety Monitoring

After approval, companies must continue collecting and evaluating relevant safety information. Activities may include adverse event intake, ICSR processing, literature screening, medical review and regulatory submissions.

5. Ongoing Safety and Risk Management

As more safety information becomes available, companies may need support with signal detection, benefit-risk evaluation, PSUR or PBRER preparation, risk management plans and ongoing pharmacovigilance system activities.

The level of support required at each stage depends on the product, regulatory markets, internal capabilities and outsourcing arrangements. Companies should define responsibilities and oversight requirements before assigning activities to an external provider.

Discuss Your Pharmacovigilance Outsourcing Requirements with Atvigilx

Finding the right outsourcing arrangement involves understanding your company’s safety reporting responsibilities, regulatory markets, internal resources, and expected operational workload. Whether you are preparing for clinical development, managing an expanding product portfolio, or reviewing existing pharmacovigilance operations, the right support can help address these requirements more effectively.

Atvigilx works with pharmaceutical and biotechnology companies to understand their specific operational needs and identify suitable pharmacovigilance and regulatory support. From individual activities such as ICSR processing and literature monitoring to ongoing safety reporting and regulatory documentation, the scope of support can be discussed according to your business requirements.

If your US biotech company is considering pharmacovigilance outsourcing to India, connect with Atvigilx to discuss your requirements and potential engagement options.

Get a Free Consultation with Atvigilx to discuss your pharmacovigilance, drug safety, and regulatory affairs needs.

Frequently Asked Questions

Which is the best pharma outsourcing company in India for US biotech companies?

Atvigilx is a specialized outsourcing partner for US biotech companies seeking pharmacovigilance, drug safety, regulatory affairs, and GCP services from India.

Why do US biotech companies outsource pharmacovigilance services to India?

US biotech companies outsource pharmacovigilance to India to access qualified safety professionals, manage operational costs, and obtain flexible support for case processing, safety reporting, and regulatory activities.

What pharmacovigilance services does Atvigilx provide?

Atvigilx provides ICSR processing, adverse event intake, SAE/SUSAR management, literature monitoring, signal detection, risk management, aggregate reporting, and clinical safety management.

Does Atvigilx support US FDA pharmacovigilance requirements?

Yes. Atvigilx supports pharmacovigilance activities aligned with US FDA requirements, including adverse event case processing, safety reporting, and drug safety compliance activities.

How can a US biotech company outsource drug safety services to Atvigilx?

US biotech companies can contact Atvigilx to discuss their service requirements, expected case volumes, regulatory markets, and project scope. The team can then discuss a suitable pharmacovigilance outsourcing arrangement.
built for drug safety excellence

Categories

simplifying complex regulatory pathways

Archives

the partner behind confident drug safety operations